← SynDRA
TALNETANT
SynDRA canonical compound SYN0000424 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | TACR3 |
|---|
| Mechanism of action | Tachykinin antagonist |
|---|
All known targets
Mechanisms of action (all sources)
- Tachykinin antagonist
- TACR3 ANTAGONIST
- Neurokinin 3 receptor antagonist
- TACR2 ANTAGONIST
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ABCB11
- CYP1A2
- CYP2C19
- CYP2C9
- CYP3A4
- OPRM1
- TACR1
- ADORA1
- ADORA3
- CCKBR
- CYP2D6
- HDAC6
- NR1I2
- OPRK1
- PTGER4
- TSPO
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Cross-references
Synonyms
- SB-223412
- CHEMBL10188
- Talnetant [INN]
- N-((S)-alpha-Ethylbenzyl)-3-hydroxy-2-phenylcinchoninamide;N-(alpha-Ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide
- 3-hydroxy-2-phenyl-N-(1-phenylpropyl)quinoline-4-carboxamide
- CZ3T9T146K
- talnetantum
- RefChem:187318
- DTXCID701509648
- MFCD00944075
- SB223412
- UNII-CZ3T9T146K
- TALNETANT [WHO-DD]
- SCHEMBL74220
- GTPL2132
- orb1299718
- SCHEMBL29390363
- Talnetant (SB 223412)?
- Talnetant, >=98% (HPLC)
- EX-A894
- BIAVGWDGIJKWRM-FQEVSTJZSA-N
- GLXC-02536
- N-((S)-alpha-Ethylbenzyl)-3-hydroxy-2-phenylcinchoninamide
- BDBM50051293
- AKOS024458283
- CS-1638
- EBC-415066
- SB-2234
- NCGC00370774-02
- NCGC00370774-05
- AC-36821
- AS-72166
- HY-14552
- DB-335820
- NS00068616
- SB-223,412
- T7549
- F862027
Look up TALNETANT in the interactive SynDRA portal →